# US 11,413,341 B2 · Vaccinia viral vectors encoding chimeric virus like particles > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,413,341 B2 - Document ID: US11413341B2 - Status: Granted - Kind: B2 - Application number: 16/796,350 - Filed: 2020-02-20 - Published: 2020-09-17 - Granted: 2022-08-16 - Earliest claimed: 2016-01-08 - Assignees: GeoVax, Inc. - Applicants: GeoVax, Inc. - Inventors: Harriet Robinson; Arban Domi; Michael Hellerstein; Farshad Guirakhoo; Nathanael Paul McCurley - Web page: https://patentgrep.com/patent/US11413341B2 ## CPC - A61P 35/00: Antineoplastic agents - C12N 15/86: Viral vectors - A61K 39/00117: {Mucins, e.g. MUC-1} - A61P 37/04: Immunostimulants - A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells} - A61K 2039/53: {DNA (RNA) vaccination} - A61K 2039/55522: {Cytokines; Lymphokines; Interferons} - C12N 7/045: {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered} - C12N 2710/24123: Virus like particles [VLP] - C12N 2710/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C12N 2710/24143: viral genome or elements thereof as genetic vector - C12N 2770/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The compositions and methods are described for generating an immune response to an antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens as a fusion product with a viral glycoprotein and matrix protein for generating a protective immune response to a subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat diseases. ## Claims ### Claim 1 A recombinant modified vaccinia Ankara (MVA) viral vector comprising: (i) a first heterologous nucleic acid sequence encoding a chimeric protein comprising (a) a mucin-1 (MUC-1) antigenic peptide and (b) a transmembrane domain of a viral glycoprotein (GP) of Marburg virus, wherein the first heterologous nucleic acid sequence encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 15, or an amino acid sequence 98% identical thereto, and (ii) a second heterologous nucleic acid sequence encoding a viral Marburg virus VP40 matrix protein; wherein the first heterologous nucleic acid sequence and second heterologous nucleic acid sequence are under the control of one or more promoters compatible with poxvirus expression systems, and wherein upon expression, the chimeric protein and VP40 matrix protein are capable of assembling together to form virus like particles (VLPs). ### Claim 2 (depends on 1) The recombinant MVA viral vector of claim 1, wherein the promoter is selected from the group consisting of Pm2H5, Psyn II, and PmH5, or combinations thereof. ### Claim 3 (depends on 1) The recombinant MVA viral vector of claim 1, wherein the first heterologous nucleic acid sequence-encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO:15. ### Claim 4 (depends on 2) The recombinant MVA viral vector of claim 2, wherein the first heterologous nucleic acid sequence is under the control of the PmH5 promoter. ### Claim 5 (depends on 2) The recombinant MVA viral vector of claim 2, wherein the second heterologous nucleic acid sequence is under the control of the PmH5 promoter. ### Claim 6 (depends on 1) The recombinant MVA of claim 1, wherein the first heterologous nucleic acid sequence is inserted between essential genes of MVA I8R and G1L. ### Claim 7 (depends on 1) The recombinant MVA of claim 1, wherein the second heterologous nucleic acid sequence is inserted in restructured and modified MVA deletion III region between MVA genes A50R and B1R. ### Claim 8 (depends on 1) The recombinant MVA viral vector of claim 1, wherein the first heterologous nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 16, or a nucleic acid sequence at least 95% identical thereto. ### Claim 9 (depends on 8) The recombinant MVA viral vector of claim 8, wherein the first heterologous nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 16. ### Claim 10 (depends on 1) The recombinant MVA viral vector of claim 1, wherein the first heterologous nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 18, or a nucleic acid sequence at least 95% identical thereto. ### Claim 11 (depends on 10) The recombinant MVA viral vector of claim 10, wherein the first heterologous nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 18. ### Claim 12 (depends on 1) The recombinant MVA viral vector of claim 1, wherein the first heterologous nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 29, or a nucleic acid sequence at least 95% identical thereto. ### Claim 13 (depends on 12) The recombinant MVA viral vector of claim 12, wherein the first heterologous nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 29. ### Claim 14 A recombinant MVA viral vector comprising: (i) a first heterologous nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO:29 encoding a chimeric protein comprising the amino acid sequence of SEQ ID NO: 15, and (ii) a second heterologous nucleic acid sequence encoding a viral Marburg virus VP40 matrix protein; wherein the first heterologous nucleic acid sequence and second heterologous nucleic acid sequence are under the control of a PmH5 promoter; wherein the first heterologous nucleic acid sequence is inserted between essential genes of MVA I8R and G1L; wherein the second heterologous nucleic acid sequence is inserted in restructured and modified MVA deletion III region between MVA genes A50R and B1R; and, wherein upon expression, the chimeric protein and VP40 matrix protein are capable of assembling together to form VLPs.